Literature DB >> 21427163

The possible risk of cancer in claudicants.

Bettina-Maria Taute1, Stephan Thommes, Ralf Taute, Hubert Podhaisky.   

Abstract

The aim of this study was to select a group of patients who had mild intermittent claudication and were undergoing secondary prevention measures, and record all vascular and non-vascular events over a 10-year follow-up. A total of 534 events were recorded in 109 claudicants. 25.7% of the claudicants died, 39% of them due to vascular events, 36% from cancer and 25% from other causes. 17 of the 20 cancer cases could be classified as related to smoking. Cancer occurred relatively early in the study, within the first five years, while severe vascular events occurred mainly during later periods. A clear transformation occurred in the outcome of the claudicants. Mortality was equally attributable to vascular and cancer-related comorbidities. In conclusion, the improvement of vascular outcomes due to secondary prevention measures and technological advances in the management of acute vascular events may result in a relative increase in cancer incidence and deaths.

Entities:  

Mesh:

Year:  2011        PMID: 21427163     DOI: 10.1177/0003319711400308

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  2 in total

1.  The fate of patients with intermittent claudication in the 21st century revisited - results from the CAVASIC Study.

Authors:  Barbara Rantner; Barbara Kollerits; Johannes Pohlhammer; Marietta Stadler; Claudia Lamina; Slobodan Peric; Peter Klein-Weigel; Hannes Mühlthaler; Gustav Fraedrich; Florian Kronenberg
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

2.  Peripheral arterial disease and systematic detection of circulating tumor cells: rationale and design of the DETECTOR prospective cohort study.

Authors:  Alexandra Yannoutsos; Manon Fontaine; Alexandre Galloula; Diane Damotte; Gilles Chatellier; Patrizia Paterlini-Bréchot; Guy Meyer; Jean Pastre; Véronique Duchatelle; Valéria Marini; Karl-Léo Schwering; Isabelle Lazareth; Parinaz Ghaffari; Audrey Stansal; Hélène Sanson; Cécile Labrousse; Hélène Beaussier; Nesrine Ben Nasr; Marc Zins; Sergio Salmeron; Emmanuel Messas; Jean-Patrick Lajonchère; Joseph Emmerich; Pascal Priollet; Jean Trédaniel
Journal:  BMC Cardiovasc Disord       Date:  2019-09-13       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.